Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
LELYSTAD, The Netherlands, April 6 /PRNewswire/ -- Today, Pepscan reports
that it has achieved a major scientific breakthrough through the use of its
CLIPS-based synthetic peptide immunogen technology. By constructing synthetic
3D mimics of the ligand binding-site on CXCR7 it has induced funct...
Scientists grow 'nanonets' able to snare added energy transfer
CHESTNUT HILL, MA (September 2, 2008) Using two abundant and relatively inexpensive elements, Boston College chemists have produced nanonets, a flexible webbing of nano-scale wires that multiplies surface area critical to improving the performance of the wires in electronics and energy applicatio...
SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
... For example, we may not obtain regulatory approval for our products, which would materially impair our ability to generate revenue, or we may not be able
to raise capital or generate revenue to finance our operations. Additional assumptions, risks and uncertainties are described in detail in our reg...
Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
...vesting in our industry. While there can be no assurance, we hope, if we obtain positive results from the analysis of our trial data, that we will be able
to attract new capital from investors and/or through potential strategic alliances that will allow us to pursue future clinical and non-clinical trial...
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
...oncerning Actimmune for the treatment of IPF; (iii) reimbursement risks associated with third-party payors; (iv) risks related to whether InterMune is able
to obtain, maintain and enforce patents and other intellectual property; (v) risks related to significant regulatory, supply and competitive barriers ...
PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan
...ng this terrible disease," says Dr. Fillit. "And this all started with an idea from Frank Longo that many thought was a little improbable. But ADDF is able
to take chances on high-risk ideas - we know that this is often where the best solutions come from."
"And PharmatrophiX's exclusive collaborat...
Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
For example, Genentech may not be able
to replicate in later trials any
favourable ...rials of GDC-0449, and Debiopharm may
not be able
to successfully advance CUDC-305 into clinical tri...through its collaborations.
- Curis may not be able
to obtain or maintain the intellectual
Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti-Infection Treatments
...r to support the development of
this important product. Based on our extensive experience, industry expertise
and first class facilities we hope to be able
to add considerable value and
flexibility to Omnio Healer's development program."
About Omnio Healer
Omnio Healer AB is a pioneer compan...
The Breast Cancer Therapeutics Market in Australia
... from all seven perspectives of the Complex Business Universe, the Growth Partnership Services programme ensures that you and your Growth Team(TM) are able
to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new oppor...
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
...l trials or meet the projected development timelines for the drug candidates in its pipeline, including Zerenex and KRX-0401; that the Company will be able
to raise additional capital in the future in order to fund its operations; or that the Company's stock will not be affected by other risk factors iden...
Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
...quire substantial additional funding in order to obtain regulatory approval for and commercialize Acetavance, and the risk that the company may not be able
to raise sufficient capital when needed, or at all; and other risks detailed in Cadence's prior press releases as well as in Cadence's periodic public...
GeoVax Labs, Inc. Provides Clinical Studies Update
...eficiency virus (SIV) prototype of the GeoVax HIV vaccine in SIV-infected primate animal models have held high promise that the GeoVax vaccine will be able
to contribute to the control of HIV-1 in already infected humans. Our team is working hard to develop the clinical trial protocol and to assemble all...
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
..."PDUFA") for INTUNIV was July
27, 2009. Shire has received a Complete Response Letter from the FDA
for INTUNIV. Shire and the FDA were not able
to reach agreement on
final product labeling in time to meet the PDUFA date. The FDA did not
identify safety concerns regarding INTUNIV, r...
Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
...atients, the company has revised the dosing regimen and expects to initiate a new trial of CERE-120 in the near future.
"We are pleased to be able
to gather unique, long-term data from both CERE-120 treated and control patients and thus gain more information about the potential long-term effects ...
Cord Blood America Retires $2.53M Obligation
...the put option agreement obligation with SIOF remaining on its balance sheet. Cord Blood America regards this as a key milestone on its path to being able
to operate debt free," said Matthew Schissler, Cord Blood America Founder and CEO. "Shelter Island provided us with the capital to purchase CorCell, ...
Plastics that convert light to electricity could have a big impact
... polymers as they are being created in a baking process, called annealing, that is used to improve the materials' performance.
The researchers are able
to measure directly how much current each tiny bubble and channel carries, thus developing an understanding of exactly how a solar cell converts light...
DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
..., orphan drug designation also positions DOR to be able
to take advantage of a wide range of financial and... statements. DOR cannot assure you that it will be able
to successfully develop or commercialize products ... research and development efforts, that it will be able
to successfully obtain any further grants and awar...
New Director of Lab Sales for Polymathic Analytical Labs
... sales leadership within competitive markets," said Chris Given, Laboratory Manager. "With Bill's expertise and proven track record, we will be better able
to assess the needs of our partners, meet customer demands and maintain lasting business relationships."
Kerr is a graduate of the University o...
Rapid heating prepares energy-saving zeolite for greater role in industrial separations
...0 degrees Centigrade in one minute, maintaining this temperature for up to two minutes and then quickly cooling it, the researchers say they have been able
to eliminate the formation of grain boundary defects that undermine the sieve-like quality of zeolite's uniformly sized nanopores.
The research gro...
Global Jatropha Hi-Tech Agricultural Training Programme (JWTP)
...ning Programme is a great place to become educated on the many sustainable feedstocks for building a successful biodiesel and afterward, attendees are able
to focus on their goals. Just imagine, by simply attending this action-packed 5-day session, you will be handed the tools to re-think, re-align and tr...
Model predicts evolution of Mediterranean landscape following fires
...cal tools used in artificial intelligence to track the movement of linked objects within a grid (in this case a map).
Millington says this model is able
to represent landscapes over areas in excess of 1,000 hectares on a map with high spatial resolution (of 0.01 - 10 ha) and over timescales ranging fro...
Bacteria pack their own demise
...ternal time bomb', a deadly mechanism that can be used against them. After years of work, VIB researchers at the Vrije Universiteit Brussel (VUB) were able
to determine the structure and operating mechanism of the proteins involved. This clears the road for finding ways to set the clock on this internal t...
TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction
...r when it becomes available because it will contain important information about Raptor and TorreyPines. Raptor's and TorreyPines' stockholders will be able
to obtain a copy of the joint proxy statement/prospectus, as well as other filings containing information about Raptor and TorreyPines, without charge...
Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing
...RATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES.
In addition to receiving the proxy statement from the Company by mail, shareholders will be able
to obtain the proxy statement, as well as other filings containing information about the Company, without charge, from the SEC's website ( http://ww...
Biopolymers Symposium 2009 Teams with Carbonfund.org to Create a Zero-Carbon Event
...use of the nature of the topics, as both our speakers and delegates seriously care for their carbon footprint."
Convention attendees are also able
to offset the emissions relating to their air travel by visiting www.biopolymersummit.com and using the calculator provided by CarbonFund.org. All ...
Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results
...ontrolled substances in many of our core products; our exposure to product liability claims and product recalls and the possibility that we may not be able
to adequately insure ourselves; our ability to protect our proprietary technology; our ability to successfully implement our in-licensing and acquisit...
First genetically engineered malaria vaccine to enter human trials
...ction. He said it was hoped the vaccine would produce similar results in humans. "Although two genes have been deleted the parasite is still alive and able
to stimulate the body's protective immune system to recognize and destroy incoming mosquito-transmitted deadly parasites," Professor Cowman said.
Sangamo BioSciences Reports Second Quarter 2009 Financial Results
...establish strategic partnerships. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able
to develop commercially viable ZFP-based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and u...
Video: New Way RA(TM) Talk Show Premieres Online for People Living With Rheumatoid Arthritis (RA)
...p us understand the physical and emotional impact of RA," said Norville. "Having lived through that experience with my mom, I feel fortunate that I am able
to play a role in providing an educational and entertaining resource to help people find new ways to live with RA, despite the challenges that often a...
MUSA Technology Partners Introduces Linux/Open Source Service Desk
The Linux and Open Source Service Desk is available to clients on either a corporate account or on-demand basis. MUSA's engineers are able
to utilize encrypted access methods for quick and secure remote assistance, but are also available for travel to clients who have regular on-site need...
Nanotech particles affect brain development in mice
... fetuses/pups on the 16th day of gestation and at several points after birth. Comparing these brains to those of control animals, the researchers were able
to demonstrate changes in expression of hundreds of genes. According to Takeda, "Diseases associated with these genes include those we normally consid...
Breaking barriers with nanoscale lasers
...d in metals can help you confine a light in a laser to sizes smaller than that required by the diffraction limit," Ning explains. "Eventually, we were able
to make a laser as thin as about one quarter of the wavelength or smaller, as opposed to one half."
Ning and Hill have achieved something like that...
Seasoned Dermatologist Nissan Pilest of Irvine, CA, Joins SDS Clinical Trials as Clinical Investigator for Dermatology Division
...physician to participate in our forthcoming trials."
Dr. Pilest treats a multi-ethnic patient population, making him perfectly situated to be able
to select a true cross section of patients who may qualify for the various clinical trials launched through SDS.
"This is a great opportunity...
United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients
...The preclinical studies also demonstrated that this product candidate can enhance blood vessel formation in damaged hearts.
"We are happy to be able
to begin the REGEN trial to test this promising product candidate in heart failure patients after completing very successful preclinical testing," sai...
Cynosure Reports Second Quarter 2009 Financial Results
...ues to hinder our domestic revenue performance, we believe we will see an improvement in our U.S. sales once credit loosens and more practitioners are able
to obtain financing."
"Despite the challenging environment, we remain unwavering in our commitment to technology and leading the industry throu...
FluMist(R) Begins Shipping for 2009-2010 Influenza Season
...anasal administration only.
Who may not be able
to get FluMist?
FluMist is not right for everyo...or FluMist.
The following people may not be able
to get FluMist or may be able
to get it only in certain situations: people with ...
PacificGMP and USC to Collaborate on Recombinant Protein Development and Manufacturing for Phase 1 Clinical Trial
...slightest insult or injury. There are currently only palliative treatments for DEB, so it is exciting to establish this partnership with a CMO that is able
to quickly initiate drug manufacturing for the clinical trial."
PacificGMP is a contract manufacturer and industry ...
Cardium Regains Listing Compliance with NYSE Amex
...Company Guide, the company's Plan Period will remain open until it has been able
to demonstrate compliance with the continued listing standards for two cons...are inherent in our business and financial condition and whether we will be able
to maintain listing compliance with our exchange, risks and uncertainties t...
Cell Therapeutics, Inc. Announces Exercise of Overallotment
...ecurities of the Company. The risks and uncertainties include the risk that the investors might not exercise their warrants, the Company might not be able
to continue to raise additional capital as needed to fund its operations, the Company's intentions regarding the use of proceeds, and other risk facto...
Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65.
...ollable, local currency performance. Organic sales growth data presented in this release is proforma data and excludes currency impacts. While we are able
to report currency impacts after the fact, we are unable to estimate changes that may occur later in 2009 to applicable exchange rates and are thus un...